[Modification of liver enzymes in undernourished rats treated with acetaminophen]

Miriam González-Mendoza1, Nelson Vicuña-Fernández

  • 1Departamento de nutrición y alimentación, Escuela de Nutrición, Facultad de Medicina, Universidad de Los Andes, Mérida Venezuela.

Gaceta Medica De Mexico
|November 26, 2003
PubMed

Insights

Acetaminophen, commonly used for pain and fever, may cause liver damage in malnourished rats. This study highlights potential risks in undernourished populations, even at standard doses.

Area of Science:

  • Pharmacology
  • Toxicology
  • Nutritional Science

Context:

  • Acetaminophen is a widely used analgesic and antipyretic, often considered safe for children and pregnant women.
  • Undernutrition can alter drug metabolism and increase susceptibility to toxicity.
  • Assessing the safety of common medications in vulnerable populations is crucial.

Purpose:

  • To investigate the effects of a therapeutic dose of acetaminophen on undernourished rats.
  • To evaluate potential acetaminophen-induced hepatic lesions in the context of malnutrition.

Summary:

  • Undernourished rats treated with acetaminophen (100 mg/kg) showed decreased body and hepatic weight.
  • Serum albumin levels significantly decreased in undernourished rats, with or without acetaminophen treatment.
  • Activity of liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase significantly decreased in undernourished rats treated with acetaminophen.

Impact:

  • This study suggests that acetaminophen, even at a single non-toxic dose, can induce hepatic lesions in undernourished rats.
  • Malnutrition may increase susceptibility to acetaminophen-induced hepatotoxicity.
  • Findings underscore the need for caution when administering acetaminophen to undernourished individuals.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...